STOCK TITAN

Icad Inc - ICAD STOCK NEWS

Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.

ICAD Inc. (symbol: ICAD) is a leading force in the realm of medical technology, specializing in advanced image analysis, workflow solutions, and radiation therapies designed for the early detection and treatment of cancers.

Core Business: The company’s main operations focus on providing healthcare professionals with cutting-edge tools to identify pathologies through a comprehensive range of high-performance, upgradeable computer-aided detection (CAD) solutions. These solutions are pivotal in mammography for breast cancer, magnetic resonance imaging (MRI) for breast and prostate cancers, and computed tomography (CT) for colorectal cancer. ICAD’s flagship technology, the Xoft® System, delivers radiation treatment for early-stage breast cancer via intraoperative radiation therapy (IORT) and accelerated partial breast irradiation (APBI). Additionally, the Xoft System is approved for treating non-melanoma skin cancer and endometrial cancer.

Recent Achievements and Partnerships: Recently, ICAD announced the integration of key AI-powered solutions from its ProFound™ Breast Health Suite into GE HealthCare's MyBreastAI Suite, aimed at enhancing breast cancer detection worldwide. This collaboration underscores ICAD's commitment to advancing breast health, improving diagnostic accuracy, and streamlining workflow efficiency for clinicians.

Financial Condition: As of the first quarter of 2024, ICAD reported a total revenue of $5.0 million, marking a 14% increase from the previous year. The company's gross profit stood at $4.1 million, with an operating expense reduction of 18%, showcasing robust financial health and strategic cost management.

Global Reach: ICAD’s influence extends across multiple countries including France, Belgium, Italy, Germany, Switzerland, and others, reflecting its strong international presence and commitment to global healthcare improvement.

Innovative Solutions: ICAD’s ProFound AI technology has demonstrated significant benefits in clinical studies, including improved radiologist sensitivity and specificity, reduced reading times, and decreased unnecessary patient recall rates. The company’s solutions are used by thousands of providers, serving millions of patients, and are available in over 50 countries.

Future Prospects: ICAD continues to innovate with the recent introduction of the ProFound Cloud, powered by Google Cloud, to enhance the accessibility and efficiency of mammography screening data. The company also remains committed to expanding its AI capabilities and improving patient outcomes globally through strategic partnerships and technological advancements.

For more information, visit www.icadmed.com or contact their media and investor relations at pr@icadmed.com and ir@icadmed.com respectively.

Rhea-AI Summary

iCAD (NASDAQ: ICAD), a leader in cancer detection technology, announced a webinar featuring Dr. Kathy Schilling from Boca Raton Regional Hospital on May 24, 2023. The session will showcase how ProFound AI technology enables radiologists to detect 23% more cancers without increasing recall rates. This innovative AI tech, which is FDA-cleared, enhances sensitivity by 8% and reduces false positives and reading time significantly. Dr. Schilling's presentation will highlight clinical practices and case studies that underline the effectiveness of ProFound AI. This technology has shown remarkable improvements in mammography accuracy, demonstrating its essential role in modern healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary

iCAD’s ProFound AI has shown promising results in increasing breast cancer detection rates according to new research presented at the American Roentgen Ray Society (ARRS) meeting. The studies revealed that ProFound AI enhanced radiologists' accuracy without increasing abnormal interpretation or recall rates. One study from the University of Florida demonstrated improved performance among radiologists using ProFound AI, highlighting its capability to provide vital clues for clinical decisions through lesion and case scores. These scores, ranging from 0-100, offer insights into malignancy likelihood, supporting personalized patient care. With over 7,500 installations globally, ProFound AI’s early adoption since its FDA clearance in 2018 has led to significant improvements in detection accuracy and reduced unnecessary callbacks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

iCAD has strengthened its executive leadership team with three key appointments aimed at driving growth and innovation. Effective immediately, Eric Lonnqvist has been appointed as Chief Financial Officer, bringing 15 years of experience from notable tech firms. Additionally, Vasu Avadhanula joins as Chief Product Officer on May 1, leveraging over 25 years of healthcare product development expertise, while Michelle Strong also takes on the role of Chief Operations Officer on the same date, focusing on revenue growth and brand equity. The company aims to enhance its impact in tackling women's health issues, particularly breast cancer, through strategic initiatives and partnerships. The new leaders will play crucial roles in accelerating iCAD’s growth strategy and expanding its market reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
management
Rhea-AI Summary

iCAD, Inc. (NASDAQ: ICAD) announced new clinical evidence published in the Journal of Clinical Oncology, demonstrating that ProFound AI Risk for 2D Mammography outperforms the Tyrer-Cuzick v8 risk model for assessing breast cancer risk.

This study analyzed data from 8,604 women over ten years, confirming higher accuracy for ProFound AI Risk across various demographics. The results indicate significant potential for personalized screening regimens and timely cancer detection, enhancing patient outcomes.

iCAD's technology aims to transform breast cancer screening by providing clinicians with improved insights and potentially saving lives through earlier diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
-
Rhea-AI Summary

iCAD, a medical technology leader in cancer detection and therapy, reported its financial results for the year ending December 31, 2022. Total revenue decreased by 17% to $27.9 million, with a notable 20% drop in Therapy revenue. The company is strategically focusing on its Detection business, particularly the Breast AI Suite, with new partnerships signed with Google Health and Solis Mammography. iCAD reduced annual expenses by $4.3 to $4.6 million, aiming for profitability by the end of 2024 without seeking additional capital. Despite losses, the gross profit remained stable at 71% of revenue, indicating effective cost management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
-
Rhea-AI Summary

iCAD is showcasing its Breast AI Suite at the National Consortium of Breast Centers (NCoBC) Annual Conference in Las Vegas from March 25-27, 2023. This suite enhances breast care, aligning with the FDA's recently established national breast density reporting standard. With nearly 50% of women over 40 having dense breasts, iCAD's technology empowers clinicians to provide accurate density assessments and personalized screening recommendations. The PowerLook Density Assessment is clinically proven and removes subjectivity from reporting, achieving 99.8% agreement with radiologists. iCAD aims to enhance patient care by automating and improving the accuracy of breast cancer detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
Rhea-AI Summary

iCAD (NASDAQ: ICAD), a leader in cancer detection and therapy solutions, announced plans to release its financial results for Q4 and FY 2022 post-market on March 28, 2023. The preliminary revenue for Q4 2022 is projected to be around $6.5 million. The company is restructuring its cost base to accommodate the shift from perpetual to subscription software licenses while continuing to invest in growth areas. Additionally, iCAD is working with investment bankers to explore strategic options for its Therapy business line, signaling potential changes in its business strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.56%
Tags
-
News
Rhea-AI Summary

iCAD, Inc. (NASDAQ: ICAD) announced on March 13, 2023, the resignation of Stacey Stevens as President and CEO for personal reasons, effective until April 30, 2023. Dana Brown has been appointed as the new President and CEO, retaining her role as Chairman of the Board. Stevens’ 16-year tenure saw significant achievements, such as the transition to a subscription model and strategic partnerships. Brown emphasized her commitment to enhancing iCAD's vision for AI cancer detection solutions and addressing the challenges of breast cancer. iCAD plans to file its Annual Report on Form 10-K by March 28, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.56%
Tags
management
-
Rhea-AI Summary

iCAD (NASDAQ: ICAD), a leader in cancer detection technology, presented significant clinical evidence at ECR 2023 showing that its ProFound AI® enhances radiologists' efficiency and cancer detection rates. The study revealed a 23% increase in cancer detection, finding 1.31 more cancers per 1,000 screenings without raising recall rates. iCAD showcased its Breast AI Suite, which includes tools for breast cancer detection and risk assessment. The company emphasized its AI solutions' positive impact on clinicians' workflows and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.17%
Tags
none
Rhea-AI Summary

iCAD, a leader in medical technology, will attend the BTIG Snowbird MedTech Conference from February 14-16, 2023, in Snowbird, UT. The company aims to showcase its innovative cancer detection and therapy solutions. Stacey Stevens, President and CEO, will conduct one-on-one meetings with investors during the event. Interested parties should connect with their BTIG representative for meeting requests. iCAD’s products, including ProFound AI, aim to enhance cancer detection efficacy and improve patient outcomes. For further details, visit icadmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
conferences

FAQ

What is the current stock price of Icad (ICAD)?

The current stock price of Icad (ICAD) is $1.83 as of December 20, 2024.

What is the market cap of Icad (ICAD)?

The market cap of Icad (ICAD) is approximately 46.7M.

What does ICAD Inc. specialize in?

ICAD Inc. specializes in advanced image analysis, workflow solutions, and radiation therapies for the early detection and treatment of cancers.

What are ICAD's core products?

ICAD’s core products include CAD solutions for mammography, MRI for breast and prostate cancers, and CT for colorectal cancer. The Xoft System is another key product, offering radiation treatment for early-stage breast, non-melanoma skin, and endometrial cancers.

What recent partnerships has ICAD announced?

ICAD recently announced a partnership with GE HealthCare to integrate key AI-powered solutions from its ProFound Breast Health Suite into GE's MyBreastAI Suite, enhancing breast cancer detection and workflow efficiency.

How is ICAD performing financially?

As of Q1 2024, ICAD reported $5.0 million in total revenue, a 14% increase from the previous year. The gross profit was $4.1 million with an 18% reduction in operating expenses.

Where does ICAD operate globally?

ICAD operates in countries including France, Belgium, Italy, Germany, Switzerland, and others, indicating a strong international presence.

What is the ProFound Cloud?

ProFound Cloud is an innovative solution powered by Google Cloud, designed to enhance the accessibility and efficiency of mammography screening data for radiologists.

What are the benefits of ICAD’s ProFound AI technology?

Clinical studies show that ICAD’s ProFound AI improves reading sensitivity and specificity, reduces reading times, and decreases unnecessary patient recall rates.

How many patients and providers use ICAD's solutions?

ICAD’s solutions are used by thousands of providers, serving millions of patients across over 50 countries.

What is the Xoft System?

The Xoft System is ICAD’s radiation treatment solution for early-stage breast cancer, non-melanoma skin cancer, and endometrial cancer. It offers treatments through IORT and APBI.

How can I contact ICAD for more information?

For more information, visit www.icadmed.com or contact ICAD via pr@icadmed.com for media inquiries and ir@icadmed.com for investor inquiries.

Icad Inc

Nasdaq:ICAD

ICAD Rankings

ICAD Stock Data

46.65M
25.05M
5.63%
27.16%
0.95%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NASHUA